APL 1202

Drug Profile

APL 1202

Alternative Names: APL-1202; MetAP2 inhibitor - Asieris Pharmaceuticals; Methionine aminopeptidase type II - Asieris Pharmaceuticals

Latest Information Update: 09 Mar 2016

Price : $50

At a glance

  • Originator Asieris Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer

Most Recent Events

  • 04 Mar 2016 Asieris Pharmaceuticals, Materia Medica Chinese Academy of Medical Sciences and Chinese Academy of Military Medical Sciences agree to co-develop APL 1202 in China for Bladder cancer before March 2016 (Asieris Pharmaceuticals website, March 2016)
  • 04 Mar 2016 Asieris Pharmaceuticals in-licenses patented technology from Johns Hopkins before March 2016 (Asieris Pharmaceuticals website, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top